NASHUA, NH and Melbourne, Australia – May 1, 2017 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the first early-stage breast cancer patient was treated in Australia with intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. The patient was treated at Monash Cancer Centre, a partnership between Peter MacCallum Cancer Centre and Monash Health, in Melbourne, Australia.
“In recent years, healthcare facilities around the world have increasingly adopted the Xoft System, recognizing the unique benefits this revolutionary technology offers to both patients and clinicians in treating a range of different cancers,” said Ken Ferry, CEO of iCAD. “We are pleased to join with Monash Cancer Centre to provide unprecedented access to this advanced treatment option to patients in Australia.”
In March 2017, Monash Cancer Centre became the first medical center in Australia to adopt the Xoft System through iCAD’s local distribution partner, Regional Health Care Group Pty Ltd. The system is FDA cleared, CE marked, entered in the Australian Register of Therapeutic Goods (ARTG), and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancer.
Ad Statistics
Times Displayed: 113248
Times Visited: 6741 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
For the treatment of early-stage breast cancer, IORT with the Xoft System allows radiation oncologists and breast surgeons to work together to administer one precise, concentrated dose of radiation to a tumor site at the time of lumpectomy. IORT with the Xoft System can be completed in as little as eight minutes, making it possible to replace six to eight weeks of traditional radiation therapy with a single treatment.
The Xoft System’s miniaturized x-ray source can be inserted into a variety of applicators that are specifically designed for certain clinical indications. Monash Cancer Centre will offer the complete suite of Xoft System applicators used to deliver IORT, skin eBx, endometrial and cervical cancer radiation treatment.
“Our adoption of the Xoft System underscores our commitment to providing optimal quality of care to our patients and we are proud to be the first to offer this technology to patients in Australia in the context of an international clinical trial,” said Dr. Steven David, MBBS, FRANZCR, Radiation Oncologist, Moorabbin Campus Director, Peter MacCallum Cancer Centre. “In our detailed review of the range of available radiation therapy solutions, the Xoft System’s distinguished versatility across a variety of clinical applications, mobility, and unique patient benefits made it the preeminent solution for our practice.”
